secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maze Therapeutics, Inc. (MAZE)
CIK:        0001842295
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0001193125-26-037747
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 1.02, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Maze Therapeutics enters $200M Hercules Capital term loan facility; initial $40M funded
--------------------------------------------------------------------------------

- Up to $200M senior secured term loan from Hercules Capital; initial $40M (Tranche 1A) funded Feb 4, 2026.
- Interest rate based on WSJ prime rate with floors 7.95%–9.25%; interest-only period up to 60 months with milestones.
- Maturity Feb 1, 2031; prepayment premiums up to 3% within first 12 months, plus exit fee of 3.95%–6.45%.
- Covenants include minimum cash requirement of 50% of outstanding loan unless market cap >$450M or >$750M.
- Prior Banc of California loan terminated and security released concurrent with this facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526037747/0001193125-26-037747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526037747/d34522d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-037747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer